← Back to Search

Metabolic Profiling for Chronic Lymphocytic Leukemia

N/A

Recruiting

Led By Christopher Fletcher, MD

Research Sponsored by University of Wisconsin, Madison

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

No previous history of cancer

Adult (18 years of age or older)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 hours (± 5 minutes)

Awards & highlights

No Placebo-Only Group

Summary

This trial will help researchers develop a method to study cancer cell metabolism and fuel preferences in patients with chronic lymphocytic leukemia.

Who is the study for?

This trial is for adults over 18 with or without Chronic Lymphocytic Leukemia (CLL). Group A includes healthy adults, Group B includes those newly diagnosed with low-burden CLL, and Group C has individuals with high-burden CLL affecting bone marrow. All must consent to participate.

What is being tested?

The study tests how leukemic cells process nutrients differently from normal cells by using special forms of glucose and glutamine ([13C5]glutamine, [U-13C]glucose) that can be tracked in the body to understand cancer cell metabolism.

What are the potential side effects?

Since this trial focuses on metabolic profiling rather than treatment, side effects are minimal but may include discomfort at injection sites or allergic reactions to tracers.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have never had cancer before.

Select...

I am 18 years old or older.

Select...

I have CLL with a low disease burden, meaning my blood counts are near normal and there's no significant swelling of lymph nodes, spleen, or liver.

Select...

My CLL is advanced, affecting my bone marrow and blood cell counts.

Select...

I have not received any treatment for my condition.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 hours (± 5 minutes)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 hours (± 5 minutes)

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 hours (± 5 minutes) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Amount of [U-13C15N]L-glutamine incorporation into metabolites in normal and leukemic lymphocytes: LCMS pharmacokinetic analysis

Amount of [U-13C]glucose incorporation into metabolites in normal and leukemic lymphocytes: Liquid chromatography-mass spectrometry (LCMS) pharmacokinetic analysis

Other study objectives

Validate ex vivo labeling model to assay metabolism